在第一线和耐火/复发环境中患有高风险神经母细胞瘤的患者中进行dinutuximab beta维护疗法-现实世界数据
Aleksandra Wieczorek1,2, Urszula Żebrowska2, Marek Ussowicz3
1Department of Pediatric Oncology and Hematology, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Journal of clinical medicine
|August 26, 2023
概括
丁西马布β显示可行性和高风险神经母细胞瘤 (HR-NB) 维护的好处,包括复发/耐药 (R/R) 病例. 现实世界的数据证实了它在波兰临床实践中的有效性.
科学领域:
- 儿科瘤学 儿科瘤学
- 免疫治疗是一种免疫疗法.
- 临床实践研究 临床实践研究
背景情况:
- 丁西马布β被批准用于高风险神经母细胞瘤 (HR-NB) 维持治疗.
- 有限的现实世界的数据存在于其在临床实践中的使用,特别是复发/耐药 (R/R) 患者.
研究的目的:
- 评估 HR-NB 患者中丁西马布β 的实际有效性和耐受性.
- 在波兰队列中评估一线和R / R设置中的结果.
主要方法:
- 在波兰三个中心对54名HR-NB患者的临床记录进行了回顾性审查.
- 患者接受了dinutuximab beta作为一线维护药物 (37名患者) 或用于R/R疾病 (17名患者).
- 对治疗反应,无进展生存期 (PFS) 和总生存期 (OS) 的分析.
主要成果:
- 在一线组中,3年PFS为0.63和OS为0.80;中位数的OS为24.37个月.
- 在R/R组,3年PFS为0.75和OS为0.86;中位数的OS为33.1个月.
- 丁西马布β被很好地容忍,即使在患有并发症或先前有毒性的患者中也是如此.
结论:
- 在现实临床实践中,dinutuximab beta对于HR-NB的维护是可行的和有益的.
- 该药物在一线和R / R设置中都表现出有效性.
- 治疗通常耐受良好,支持其在常规护理中的使用.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
